|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:Aventis_(2004)
gptkb:Genzyme_(2011)
Ablynx (2018)
Bioverativ (2018)
Principia Biopharma (2020)
Synthélabo (1999)
Translate Bio (2021)
|
|
gptkbp:CEO
|
gptkb:Paul_Hudson
|
|
gptkbp:country
|
gptkb:France
|
|
gptkbp:founded
|
1973
|
|
gptkbp:founder
|
gptkb:Jean-François_Dehecq
|
|
gptkbp:headquartersLocation
|
gptkb:Paris,_France
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sanofi
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:keyPerson
|
gptkb:Jean-François_Dehecq
gptkb:Paul_Hudson
gptkb:Serge_Weinberg
|
|
gptkbp:legalForm
|
Société Anonyme
|
|
gptkbp:listedOn
|
gptkb:SBF_120
gptkb:NYSE
gptkb:CAC_40
gptkb:Euronext_100
|
|
gptkbp:memberOf
|
gptkb:International_Federation_of_Pharmaceutical_Manufacturers_&_Associations
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
|
gptkbp:netIncome
|
€5.8 billion (2023)
|
|
gptkbp:notableProduct
|
gptkb:Amaryl
gptkb:Aubagio
gptkb:Clexane
gptkb:Dupixent
gptkb:Fluzone
gptkb:Kevzara
gptkb:Lantus
gptkb:Menactra
gptkb:Mysimba
gptkb:Pentacel
gptkb:Plavix
gptkb:Praluent
gptkb:Toujeo
Polio vaccine
|
|
gptkbp:numberOfEmployees
|
~91,000
|
|
gptkbp:parentCompany
|
none
|
|
gptkbp:previousName
|
gptkb:Sanofi-Aventis
|
|
gptkbp:products
|
vaccines
pharmaceutical drugs
consumer healthcare products
|
|
gptkbp:revenue
|
€43.07 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
gptkb:Euronext_Paris
|
|
gptkbp:stockSymbol
|
gptkb:SNY
SAN
|
|
gptkbp:subsidiary
|
gptkb:Sanofi_Pasteur
gptkb:Genzyme
gptkb:Chattem
gptkb:Sanofi_Aventis
|
|
gptkbp:website
|
https://www.sanofi.com/
|
|
gptkbp:bfsParent
|
gptkb:Warren_Buffett
|
|
gptkbp:bfsLayer
|
4
|